AUGUST 3, NYT:
YOU CAN GET A FREE PFIZER VACCINATION RIGHT NOW ADMINISTERED BY EXPERTS:
1. REPORT OF EARLY STAGES OF INHALED VACCINE IN CHINA. IT SEEMS. TO WORK! (J. Harris)
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Participants were enrolled and randomly assigned (1:1:1:1:1) into five groups to be vaccinated via intramuscular injection, aerosol inhalation, or both….Aerosolised Ad5-nCoV is well tolerated, and two doses of aerosolised Ad5-nCoV elicited neutralising antibody responses, similar to one dose of intramuscular injection. An aerosolised booster vaccination at 28 days after first intramuscular injection induced strong IgG and neutralising antibody responses. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies.”
(J. Harris: A short report that is very encouraging where Astra/Zeneka first jab patients received a second jab with Pfizer)
”…A striking increase of vaccine-induced SARS-CoV-2 surrogate neutralisation activity was observed in 229 of 232 vaccinees who received a BNT162b2 boost vaccination 9–12 weeks after ChAdOx1 nCoV-19 prime vaccination. Sera were analysed on the day of BNT162b2 boost vaccination and 2 weeks after (appendix p 5). The single non-responder reported chronic lymphatic leukaemia. High antibody levels observed in two individuals after ChAdOx1 nCoV-19 prime vaccination most likely reflected previous, undetected SARS-CoV-2 infection….Although we report a non-blinded and non-randomised study, the results obtained in more than 480 individuals who were primed with an adenoviral vector-based and boosted with an mRNA COVID-19 vaccine indicate increased efficacy of a heterologous prime–boost vaccination. This vaccination scheme is an interesting option if the thrombosis risk posed by adenoviral vector-based vaccines is a concern, and it increases flexibility in a setting of vaccine shortage. However, further studies need to address the safety and clinical efficacy of heterologous vaccination regimens.
A blurb from the 3 Aug. NYT:…”The surge is patchwork, flaring more in some states than in others. Friday, Florida set a record for its peak single-day caseload at nearly 21,700 new infections. That state, the site of more than 1 in 5 cases nationally, is the epicenter of this latest U.S. wave. But that, so far, has not persuaded Florida leadership to mandate masks in schools. Parents can choose whether students wear masks when Florida’s academic year begins, Florida Gov. Ron DeSantis (R) announced Friday.”
FROM THE ATLANTIC:
J. Harris: Good article that explains the difficulties in supplying vaccine to “everyone.”
AND LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.